Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors

Pigment Cell and Melanoma Research

Volumn 27, Issue 2, 2014, Pages 253-262

  Choi, Jaehyuk ^a   Landrette, Sean F ^a   Wang, Tiffany ^a   Evans, Perry ^a   Bacchiocchi, Antonella ^a   Bjornson, Robert ^b   Cheng, Elaine ^a   Stiegler, Amy L ^a   Gathiaka, Symon ^c   Acevedo, Orlando ^c   Boggon, Titus J ^a   Krauthammer, Michael ^a   Halaban, Ruth ^a   Xu, Tian ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University   (United States)

^c AUBURN UNIVERSITY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

BRAF; Drug resistance; Melanoma; Paradox blockers; PLX4032

Indexed keywords

BRAF; DRUG RESISTANCE; MELANOMA; PARADOX BLOCKERS; PLX4032;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TRANSPOSABLE ELEMENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; MUTANT PROTEINS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84894069940     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12197     Document Type: Article

References (33)

1. Abel, E.V., Basile, K.J., Kugel, C.H. III et al. (2013). Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J. Clin. Invest. 123, 2155-2168.
2. Barbieri, C.E., Baca, S.C., Lawrence, M.S. et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689.
3. Bollag, G., Hirth, P., Tsai, J. et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
4. Botton, T., Yeh, I., Nelson, T. et al. (2013). Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res. 26, 845-851.
5. Dahlman, K.B., Xia, J., Hutchinson, K., et al. (2012). BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2, 791-797.
6. Diaz, L.A. Jr, Williams, R.T., Wu, J. et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540.
7. Ding, S., Wu, X., Li, G., Han, M., Zhuang, Y., and Xu, T. (2005). Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122, 473-483.
8. Girotti, M.R., Pedersen, M., Sanchez-Laorden, B. et al. (2013). Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158-167.
9. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 89, 5547-5551.
10. Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., Mccusker, J.P., Kluger, Y., and Sznol, M. (2010). PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190-200.
11. Haq, R., Yokoyama, S., Hawryluk, E.B. et al. (2013). BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc. Natl Acad. Sci. USA 110, 4321-4326.
12. Hartsough, E., Shao, Y., and Aplin, A.E. (2013). Resistance to RAF inhibitors revisited. J. Invest. Dermatol. [Epub ahead of print].
13. Janne, P.A., Gray, N., and Settleman, J. (2009). Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709-723.
14. Landrette, S.F., Cornett, J.C., Ni, T.K., Bosenberg, M.W., and Xu, T. (2011). piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS ONE 6, e26650.
15. Le, K., Blomain, E.S., Rodeck, U., and Aplin, A.E. (2013). Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 26, 509-517.
16. Maertens, O., Johnson, B., Hollstein, P. et al. (2013). Elucidating Distinct Roles for NF1 in Melanomagenesis. Cancer Discov. 3, 338-349.
17. Montagut, C., Sharma, S.V., Shioda, T. et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861.
18. Narayan, A., Carriero, N.J., Gettinger, S.N., Kluytenaar, J., Kozak, K.R., Yock, T.I., Muscato, N.E., Ugarelli, P., Decker, R.H., and Patel, A.A. (2012). Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 72, 3492-3498.
19. Navin, N., Kendall, J., Troge, J. et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94.
20. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
21. Ni, T.K., Landrette, S.F., Bjornson, R.D., Bosenberg, M.W., and Xu, T. (2013). Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. Proc. Natl Acad. Sci. USA 110, E3640-E3649.
22. Paraiso, K.H., Xiang, Y., Rebecca, V.W. et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760.
23. Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390.
24. Shi, H., Moriceau, G., Kong, X. et al. (2012). Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724.
25. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New Engl. J. Med. 366, 707-714.
26. Straussman, R., Morikawa, T., Shee, K. et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
27. Swift, S., Lorens, J., Achacoso, P., Nolan, G.P. (2001). Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr. Protoc. Immunol. edited by John E. Coligan. [et al.] Chapter 10, Unit 10 17C.
28. Szulc, J., Wiznerowicz, M., Sauvain, M.O., Trono, D., and Aebischer, P. (2006). A versatile tool for conditional gene expression and knockdown. Nat. Methods 3, 109-116.
29. Turke, A.B., Zejnullahu, K., Wu, Y.L. et al. (2010). Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88.
30. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr, and Kinzler, K.W. (2013). Cancer genome landscapes. Science 339, 1546-1558.
31. Wagenaar, T.R., Ma, L., Roscoe, B., Park, S.M., Bolon, D.N., and Green, M.R. (2013). Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Pigment Cell Melanoma Res. [Epub ahead of print].
32. Whittaker, S.R., Theurillat, J.P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G.S., Schadendorf, D., Root, D.E., and Garraway, L.A. (2013). A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition. Cancer Discov. 3, 350-362.
33. Wilson, T.R., Fridlyand, J., Yan, Y. et al. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509.